RxDoctor Payments Data

Audrius Ruksenas, MD

Internal Medicine · Cincinnati, OHNPI 1447202106

Payments from drug & device makers

$48,687in general payments, 2019–2025

Across 6 payments — averaging $8114.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Currax Pharmaceuticals LLC$30K
  • AstraZeneca$19K
  • Teva Pharmaceuticals USA, Inc.$111

What the payments were for

  • Education$111100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$48,687 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$324,135
Medicare patients
670
Services billed
3,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,452$381,480
XifaxanRifaximin139$136,759
NuplazidPimavanserin Tartrate29$122,135
TrulicityDulaglutide153$111,049
XareltoRivaroxaban382$97,397
AustedoDeutetrabenazine30$90,617
IngrezzaValbenazine Tosylate23$86,482
JardianceEmpagliflozin327$80,376
MyrbetriqMirabegron363$69,710
JanuviaSitagliptin Phosphate168$50,009
FarxigaDapagliflozin Propanediol251$48,362
RexultiBrexpiprazole68$43,563
OzempicSemaglutide39$39,807
DovatoDolutegravir Sodium/Lamivudine12$36,743
EntrestoSacubitril/Valsartan127$33,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$111$90,61730 claims
AstraZenecaFarxiga$18,500$48,362251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →